This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

36/100

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

A doença de Alzheimer (DA) é uma enfermidade neurodegenerativa progressiva cuja fisiopatologia envolve, entre outros mecanismos, o acúmulo cerebral de β-amiloide, associado a alterações da proteína tau, sua hiperfosforilação e formação de emaranhados neurofibrilares, contribuindo para a disfunção sináptica e a perda neuronal. Essas alterações podem ocorrer anos antes do surgimento das manifestações clínicas, reforçando a necessidade de estratégias capazes de identificar a doença em estágios iniciais. Nesse contexto, esse artigo buscou avaliar a utilização da proteína tau fosforilada na treonina 217 (p-tau217) como biomarcador sanguíneo na identificação precoce da DA, considerando sua relação com as alterações neuropatológicas e suas possíveis aplicações diagnósticas. Foi realizada uma revisão integrativa da literatura nas bases PubMed e Biblioteca Virtual em Saúde (BVS), utilizando os descritores “Alzheimer Disease” e “p-tau217”, combinados pelo operador booleano AND. Foram incluídos estudos observacionais e ensaios clínicos controlados publicados entre 2024 e 2026, disponíveis gratuitamente e com texto completo, sendo selecionados 26 estudos. Os resultados indicaram associação entre os níveis plasmáticos de p-tau217 e alterações relacionadas à deposição de β-amiloide e à patologia tau, além de sua aplicação na identificação de alterações pré-clínicas, estratificação de pacientes e acompanhamento longitudinal. Conclui-se que o p-tau217 apresenta potencial para integrar a investigação da DA, embora sua aplicação clínica ainda dependa de maior padronização laboratorial e definição de pontos de corte.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. This review of 26 studies found that blood levels of p-tau217 were associated with amyloid deposition and tau pathology and with identifying preclinical changes and stratifying patients. The authors present p-tau217 as a promising blood biomarker for early identification of Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Filho, P. E. M. d. M., Campos, V. M., Bueno, A. C. d. M., da Silva, M. E. M. P., & Rodrigues, M. A. d. A. S. (2026). P-TAU217 COMO BIOMARCADOR SANGUÍNEO NO DIAGNÓSTICO PRECOCE DA DOENÇA DE ALZHEIMER: UMA REVISÃO DA LITERATURA. Revista Ibero-Americana de Humanidades, Ciências e Educação. https://doi.org/10.51891/rease.v12i9.30082

Vancouver

Filho PEMdM, Campos VM, Bueno ACdM, da Silva MEMP, Rodrigues MAdAS. P-TAU217 COMO BIOMARCADOR SANGUÍNEO NO DIAGNÓSTICO PRECOCE DA DOENÇA DE ALZHEIMER: UMA REVISÃO DA LITERATURA. Revista Ibero-Americana de Humanidades, Ciências e Educação. 2026. doi:10.51891/rease.v12i9.30082.

BibTeX

@article{filho2026-b67975db,
  author  = {Filho, Paulo Eduardo Macedo de Moraes and Campos, Victor Monteiro and Bueno, Ana Carolina de Moraes and da Silva, Maria Eduarda Monteiro Pereira and Rodrigues, Maria Aparecida de Almeida Souza},
  title   = {{P-TAU217 COMO BIOMARCADOR SANGUÍNEO NO DIAGNÓSTICO PRECOCE DA DOENÇA DE ALZHEIMER: UMA REVISÃO DA LITERATURA}},
  journal = {Revista Ibero-Americana de Humanidades, Ciências e Educação},
  year    = {2026},
  doi     = {10.51891/rease.v12i9.30082},
  url     = {https://doi.org/10.51891/rease.v12i9.30082}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: this is a follow-up (cohort) study. People are observed over time and not assigned to anything, so an association can reflect other differences between groups. Look at how long follow-up lasted, how many dropped out, and whether the authors adjusted for age, education and other health conditions.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded moderate. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Moderate means the abstract mentions a cohort, case-control or longitudinal design. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Nesse contexto, esse artigo buscou avaliar a utilização da proteína tau fosforilada na treonina 217 (p-tau217) como biomarcador sanguíneo na identificação precoce da DA, considerando sua relação com as alterações neuropatológicas e suas possíveis aplicações diagnósticas.
Foi realizada uma revisão integrativa da literatura nas bases PubMed e Biblioteca Virtual em Saúde (BVS), utilizando os descritores “Alzheimer Disease” e “p-tau217”, combinados pelo operador booleano AND.
Foram incluídos estudos observacionais e ensaios clínicos controlados publicados entre 2024 e 2026, disponíveis gratuitamente e com texto completo, sendo selecionados 26 estudos.
Os resultados indicaram associação entre os níveis plasmáticos de p-tau217 e alterações relacionadas à deposição de β-amiloide e à patologia tau, além de sua aplicação na identificação de alterações pré-clínicas, estratificação de pacientes e acompanhamento longitudinal.
Conclui-se que o p-tau217 apresenta potencial para integrar a investigação da DA, embora sua aplicação clínica ainda dependa de maior padronização laboratorial e definição de pontos de corte.

Why it matters

This review of 26 studies found that blood levels of p-tau217 were associated with amyloid deposition and tau pathology and with identifying preclinical changes and stratifying patients. The authors present p-tau217 as a promising blood biomarker for early identification of Alzheimer's disease.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designlongitudinal study
Evidence strengthModerate

How this study scored 36/100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 35 of the 96 points we could judge it on, which is 36 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Revista Ibero-Americana de Humanidades, Ciências e Educação)
Journal's citation record	0 / 4	Revista Ibero-Americana de Humanidades, Ciências e Educação: journal h-index 19 (OpenAlex, 2026-10-29)
Study design	7 / 12	A longitudinal study following the same people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 2 year(s) since 2026
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Maria Aparecida de Almeida Souza Rodrigues holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record	0 / 3	University of Vassouras: institution h-index 41 (OpenAlex)
Multicenter collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	35 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 35 of the 96 points we could judge it on is 36 out of 100.
Total	36 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →